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Background. Influenza infection is a trigger of asthma attacks. Influenza vaccination can potentially reduce the incidence of 
influenza in people with asthma, but uptake remains persistently low, partially reflecting concerns about vaccine effectiveness (VE).
Methods. We conducted a test-negative designed case-control study to estimate the effectiveness of influenza vaccine in people 
with asthma in Scotland over 6 seasons (2010/2011 to 2015/2016). We used individual patient–level data from 223 practices, which 
yielded 1 830 772 patient-years of data that were linked with virological (n = 5910 swabs) data.
Results. Vaccination was associated with an overall 55.0% (95% confidence interval [CI], 45.8–62.7) risk reduction of laboratory-
confirmed influenza infections in people with asthma over 6 seasons. There were substantial variations in VE between seasons, in-
fluenza strains, and age groups. The highest VE (76.1%; 95% CI, 55.6–87.1) was found in the 2010/2011 season, when the A(H1N1) 
strain dominated and there was a good antigenic vaccine match. High protection was observed against the A(H1N1) (eg, 2010/2011; 
70.7%; 95% CI, 32.5–87.3) and B strains (eg, 2010/2011; 83.2%; 95% CI, 44.3–94.9), but there was lower protection for the A(H3N2) 
strain (eg, 2014/2015; 26.4%; 95% CI, −12.0 to 51.6). The highest VE against all viral strains was observed in adults aged 18–54 years 
(57.0%; 95% CI, 42.3–68.0).
Conclusions. Influenza vaccination gave meaningful protection against laboratory-confirmed influenza in people with asthma 
across all seasons. Strategies to boost influenza vaccine uptake have the potential to substantially reduce influenza-triggered asthma 
attacks.
Keywords. influenza; vaccination; asthma; laboratory-confirmed influenza.
Seasonal influenza results in substantial global morbidity and 
mortality each year [1, 2]. In people with asthma, influenza in-
fection can exacerbate asthma symptoms, which may result in 
asthma attacks that necessitate medical attention and, in many 
cases, hospital admission [3]. The World Health Organization 
(WHO) and national immunization programs recommend an-
nual influenza vaccination in people with asthma as the main 
prophylactic measure against influenza [4–6]. In the United 
Kingdom, however, vaccination rates in asthma remain well 
below the 75% uptake target set by the WHO [7]. This sub-
optimal vaccine uptake is due, at least in part, to uncertainty 
among people with asthma and healthcare providers around the 
effectiveness of influenza vaccines [8]. In the United Kingdom, 
suboptimal vaccine protection is partly addressed with the in-
troduction of new vaccine formulations. Specifically, in season 
2018/2019, younger adults aged 18–64 years who belonged to 
an at-risk group were offered a quadrivalent inactivated vaccine 
(QIV) and people aged >65 years were offered an adjuvanted 
trivalent inactivated vaccine (TIV) [9].The QIV aims to pro-
vide better protection by including 2 influenza B subtypes given 
that influenza B affects younger age groups. The adjuvanted 
TIV aims to enhance the immune response in older people and 
improve the current suboptimal vaccine effectiveness (VE) ob-
served from traditional TIVs [9].
Our recent systematic review suggested that the vaccine is ef-
fective against influenza infection in asthma [8]. However, the 
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conclusions of that review were based mainly on studies in which 
the overall quality was rated as low due to methodological issues 
related to the study design and conduct [8]. Two case-control 
studies published after the search date of the literature review as-
sessed VE in individuals with asthma [10]. The first study com-
pared the VE between asthma and non-asthma hospitalized 
patients for laboratory-confirmed influenza [10]. However, there 
were too few patients with asthma and, thus, the study was un-
derpowered to determine the effectiveness of the influenza vac-
cine [10]. In the second study, the VE was assessed in children 
aged 6–59  months during 4 seasons by various characteristics 
including asthma [11]. VE of 43.3% was found in the asthma 
subgroup. However, no further analyses in relation to other dem-
ographics or other characteristics related to influenza infection 
or the vaccination were performed for the asthma subgroup [11].
Most national immunization committees assess VE based on 
evidence from observational studies rather than placebo ran-
domized controlled trials, which are no longer conducted in 
asthma since the vaccination is now a public health recommen-
dation for all at-risk groups such as people with asthma [12]. 
Thus, we used a test-negative design (TND), case-control study 
to best determine the VE for each influenza season since it is 
now seen as the gold standard for generating unbiased VE es-
timates [13–16]. In addition, the large sample size of our TND 
study using swab samples from multiple seasons enabled us to 
assess various factors that affect VE in observational studies, 
such as asthma population characteristics and influenza circu-
lating types and subtypes, which were not assessed in previous 
studies due to sample size limitations [8].
Our aim in this study was to assess VE in children and adults 
with asthma. More specifically, our objectives were to evaluate 
seasonal influenza VE across and in single seasons, evaluate VE 
against common seasonal circulating viral strains, and provide 
VE estimates by age groups.
METHODS
Study Design
We undertook a retrospective, observational, TND, case-control 
study to evaluate influenza VE in patients who seek care for acute 
respiratory infection. In a TND study, cases are those who test 
positive for influenza and controls are those who test negative for 
influenza. This study included children (aged >6 months) and 
adults who were recommended by UK immunization guidelines 
to receive influenza vaccination, that is, those treated for asthma 
who require continuous or repeated use of inhaled or systemic 
corticosteroids and/or with previous exacerbations that required 
hospital admission. The study participants were identified from 
223 general practices (sentinel and nonsentinel) and hospitals 
for acute respiratory illness from influenza season 2010/2011 to 
2015/2016 in Scotland. Patients were swabbed and tested for in-
fluenza using the multiplex real-time polymerase chain reaction 
(RT-PCR) assay [17]. Patients with a positive test for influenza 
were classified as cases, while those with a negative test were 
classified as controls. In patients with more than 1 positive test 
for influenza, only the first positive test was counted as a single 
case. VE was estimated by comparing positivity proportions be-
tween the vaccinated and unvaccinated patients [16].
The VE assessment in the asthma population was an objective 
of the Seasonal Influenza Vaccine Effectiveness (SIVE) II pro-
ject [18] (see included datasets in Figure 1). See Supplementary 
Material 1 for details.
Exposure and Outcome Assessment
The exposure status was based on vaccination administrated 
between the preinfluenza season and the end of the influenza 
season. Individuals vaccinated from 1 September until the end 
of the influenza season defined the “exposed” group. Individuals 
with no vaccination record, vaccinated after being tested for in-
fluenza, or vaccinated within 14 days prior to testing were clas-
sified as the “unexposed” group [18].
General practitioners who were part of the sentinel scheme 
obtained nasal or nasopharyngeal swabs from patients with 
influenza-like illness (ILI) symptoms. General practitioners 
usually collected swab samples from patients who presented 
with ILI symptoms (independent of whether the patient had 
or had not been vaccinated) within 7 days of the date of onset 
of those symptoms. Each general practitioner collected up to 5 
samples per week and submitted those to the West of Scotland 
Specialist Virology Centre (WoSSVC) [18]. Each swab sample 
collected in general practice sentinel settings was tested at the 
WoSSVC using the multiplex RT-PCR test for a range of res-
piratory pathogens, including influenza [18]. For non-sentinel 
practices or secondary care, other laboratories were involved in 
testing. Subtype and genetic characterization was performed for 
positive influenza sentinel samples and most of the nonsentinel 
general practice and hospital samples. Data on laboratory tests 
carried out in nonsentinel primary and secondary healthcare fa-
cilities were also collected by the Electronic Communication of 
Surveillance in Scotland database. See Supplementary Material 
2 for baseline characteristics description.
Statistical Analyses
Baseline characteristics of study participants were described. 
The relation between vaccination status and baseline charac-
teristics was also provided for cases and controls. Proportions 
and odds ratios (ORs) were used to describe differences be-
tween study groups depending on the nature of each variable. 
All baseline population characteristics were presented as cate-
gorical variables, and the χ2 test was used to describe any associ-
ation in relation to exposure or outcome. Any missing data were 
reported. All tests were 2-tailed, and results were considered 
significant if P < .05. See Supplementary Materials 3 and 4 for 
details on unit of analysis and metaanalysis.
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Primary and Secondary Analyses
Prespecified subgroup analyses as per our published protocol 
included the provision of VE for influenza A  and B strains 
per season [18]. Post hoc analysis not specified in our pro-
tocol was also carried out in this study. Specifically, we strati-
fied the VE by age groups in order to investigate the age when 
immunosenescence begins in adults.
Vaccine Effectiveness
VE and the 95% confidence intervals (CIs) were estimated using 
the formula, VE = (1 – aOR) × 100 based on adjusted ORs (aORs) 
[18]. ORs were calculated by the regression coefficients of vaccine 
status in the model. A  generalized additive logistic regression 
model was used to explain the relationship between influenza 
infection and influenza vaccine in the presence of other con-
founding covariates. The model provided VE estimates adjusted 
for the effects of the following covariates: time, age, underlying 
medical conditions, and the source of swab sample collection, 
which were either statistically or epidemiologically associated 
with the outcome. Adjustment for time was performed for all 
VE estimates. Time was measured in days from the beginning 
of October each season. It was included as a spline function to 
account for bias related to time differences between influenza cir-
culation and vaccine administration during each season [18].
Sample Size
Using data from a previous study [18], we anticipated 1454 
asthma patients would be swabbed over the 2 seasons 2014–
2016. We assumed that 582 or 40.0% (1454*0.40) of asthma pa-
tients had been vaccinated for influenza and that the number 
of tests positive for influenza was 218 or 15.0% (1454*0.15), 
which gave an 80.0% power to detect a VE of 33.0% [18]. The 
study recruited 1413 patients swabbed in 2014/2015 and 1670 
swabbed in 2015/2016. Sample size details are provided in 
Supplementary Material 5. Statistical analyses were carried out 
using R Version 3.4.2 and RStudio (Version 1.0.143) [19] within 
the National Health Service Scotland data safe haven.
Ethical Considerations
The Information Services Division, National Services Scotland, 
Privacy Advisory Committee approved the linkage and the sta-
tistical analysis of the anonymized data used in this study.
Reporting
We used the Strengthening the Reporting of Observational 
studies in Epidemiology and REporting of studies Conducted 
using Observational Routinely collected Data checklists to 
guide transparent reporting of this TND, case-control study 
(see Supplementary Materials 6 and 7) [20, 21].
Figure 1. Phases of data extraction, linkage, and analysis in a secured environment. Abbreviations: CHI, Community Health Index; ECOSS-HPS, Electronic Communication 
of Surveillance in Scotland-Health Protection Scotland; GP, general practitioners; SIRS, Scottish Immunisation & Recall System-Health Protection Scotland; SIVE II, Seasonal 
Influenza Vaccine Effectiveness II project; VE, vaccine effectiveness. 
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RESULTS
A total registered primary care asthma population of 1 830 772 
person-years out of 194 319 people with asthma was recruited in 
this study over a 16-year period. These data were collected as part 
of the SIVE II study [18] and included 5910 swab samples taken 
from 5022 asthma patients from 2010/2011 to 2015/2016 (Figure 
2). These swabs were collected in primary or secondary care set-
tings from people with asthma and tested for influenza with the 
RT-PCR test. There were 781 of 5910 (13.2%) swabs that tested 
positive for influenza and were classified as cases (Table 1); 86.8% 
tested negative for influenza and were classified as controls (Figure 
2). Patients more likely to test positive for influenza were aged 
45–64 years (15.1%), lived in remote small towns (>10%), had not 
received previous seasonal influenza vaccine (15.2%), and had a 
swab sample collected in a primary care setting (16.7%; Table 2).
Vaccine Effectiveness by Season and Influenza Type and Subtype
The VE for the common influenza circulating strains was esti-
mated for each strain in each influenza season. In 2010/2011, 
the overall VE was high (76.1%; 95% CI, 55.6 to 87.1), with A/
H1N1 and B predominating (Table 3). In 2011/2012, the overall 
VE was lower and imprecise (45.1%; 95% CI, −35.1 to 77.7), 
with A/H3N2 predominating. Slightly higher and more precise 
overall VE of 45.2% (95% CI, 13.8 to 65.1) was observed in the 
2012/2013 season when all influenza A subtypes codominated. 
The overall VE in 2013/2014 (when the predominant strain was 
A/H1N1) was 52.3% (95% CI, 6.5 to 75.6). In 2014/2015, an 
overall VE of 48.6% (95% CI, 27.8 to 63.4) was found with a 
high swab positivity (16.4%) and predominant strains H3N2 
and B. In the 2015/2016 season, the overall VE of 57.8% (95% 
CI, 40.1 to 70.3) was higher compared with previous seasons 
(except for 2010/2011); the predominant strains were A/H1N1 
and B, and the swab positivity was 12.0%.
In 2010/2011, we found high VE for the influenza A(H1N1) 
subtype and B, with estimates of 70.7% (95% CI, 32.5 to 87.3) 
and 83.2% (95% CI, 44.3 to 94.9), respectively (Table 3). In the 
2011/2012 season, a small number of cases of influenza A(H3) 
subtype and B resulted in low and imprecise VE estimates of 
3.7% (95% CI, −240.5 to 75.0) and 71.8% (95% CI, −358.1 to 
98.3), respectively. In the 2012/2013 season when all influenza 
A subtypes codominated, a particularly high VE of 77.5% (95% 
CI, 9.8 to 94.4) was observed for A(H1N1), but lower VE was 
found for the cocirculating influenza A(H3) and B strains. In 
2013/2014, a VE of 32.0% (95% CI, −52.2 to 69.6) was observed 
for the influenza A(H1N1) subtype; imprecision in the VE es-
timate was due to low swab positivity. In 2014/2015, a high VE 
of 77.0% (95% CI, 53.9 to 88.5) for influenza B was found. In 
2015/2016, the swab positivity was 12.0% and a VE estimate of 
54.7% (95% CI, 19.5 to 74.5) was observed for influenza B.
Pooled Vaccine Effectiveness by Influenza Type and Subtype
The overall VE estimate was 54.9% (95% CI, 44.4 to 63.4) against 
influenza A and B types as it is shown by the OR provided in 
the random effect model (Figure 3). Heterogeneity for this 
pooled estimate was detected but it was small. A substantially 
Figure 2. Flow diagram for the test-negative design, case-control study for an asthma population for the influenza seasons 2010/2011 to 2015/2016, Scotland. 
Abbreviation: HPS, Health Protection Scotland.
Table 1. Number of Influenza (Sub)Types Out of the 781 Influenza- 
Positive Cases
Influenza (Sub)Type
Number of Influenza  
(Sub)Types per Number of Cases (%)
Influenza A 581/781 (74.4)
A(H1N1) 240/781 (30.7)
A(H3) 208/781 (26.6)
A(unknown) 133/781 (17.0)
Influenza B 205/781 (26.2)
Influenza A and B  5/781 (0.6)
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Table 2. Baseline Characteristics for Cases and Controls With Asthma During 6 Seasons, Scotland, 2010–2016
Covariate
Total Samples 
(% of Total)
Number of 
Vaccinated 
at Test 
(% of Total) P Value
Number of Positive 
Swabs 
(% of Total) P Value
Swab-Positive  
Adjusted Odds Ratioa
Adjusted 
95% Confidence  
Interval
Gender
 Female (reference) 3575 (60.5) 1777 (49.7) .04 469 (13.1) .79 NA NA
 Male 2335 (39.5) 1097 (47.0) 312 (13.4) 1.02 .88–1.19
Age group, yb
 0–1 5 (0.1) 3 (60.0) <.001 0 (0.0) .0004 8.688845e-06 1.320726e-209 to  
5.716258e+198
 2–4 169 (2.9)  64 (37.9) 11 (6.5) 0.47 .25–.90
 5–11 530 (9.0) 213 (40.2) 45 (8.5) 0.63 .44–.91
 12–17 371 (6.3) 119 (32.1)  45 (12.1) 0.94 .65–1.35
 18–44  1615 (27.3) 436 (27.0) 234 (14.5) 1.15 .90–1.47
 45–64  1625 (27.5) 826 (50.8) 246 (15.1) 1.21 .95–1.54
 65–74  747 (12.6) 549 (73.5)  91 (12.2) 0.94 .70–1.27
 ≥75 (reference)  847 (14.3) 663 (78.3) 109 (12.9) NA NA
Deprivation quintilec
 1d (reference) 1350 (22.8) 620 (45.9) .06 178 (13.2) .69 NA NA
 2 1486 (25.1) 732 (49.3) 184 (12.4) 0.93 .75–1.16
 3 1035 (17.5)  531 (51.3) 147 (14.2) 1.09 .86–1.38
 4  976 (16.5)  465 (47.6) 130 (13.3) 1.01 .79–1.29
 5  938 (15.9)  475 (50.6) 116 (12.4) 0.93 .72–1.19
Urban/rural scoree
 1 (reference) 3210 (54.3) 1573 (49.0) .003 352 (11.0) <.001 NA NA
 2 1459 (24.7)  676 (46.3) 228 (15.6) 1.50 1.26–1.80
 3 381 (6.4)  183 (48.0)  63 (16.5) 1.61 1.19–2.14
 4  91 (1.5)  40 (44.0)  16 (17.6) 1.73 .97–2.93
 5  54 (0.9)  22 (40.7)  14 (25.9) 2.84 1.48–5.15
 6 448 (7.6)  253 (56.5)  57 (12.7) 1.18 .87–1.58
 7  63 (1.1)  24 (38.1)  16 (25.4) 2.76 1.51–4.82
 8f  118 (2.0)  65 (55.1)  17 (14.4) 1.37 .78–2.25
Chronic obstructive pulmonary 
disease
 775 (13.1) 522 (67.4) <.001 95 (12.3) .40 0.91 .72–1.13
Chronic heart disease  722 (12.2) 527 (73.0) <.001 92 (12.7) .69 0.95 .75–1.20
Chronic liver disease 112 (1.9)  56 (50.0) .77 15 (13.4) .96 1.02 .56–1.70
Chronic neurological disease 357 (6.0) 251 (70.3) <.001 45 (12.6) .73 0.94 .68–1.29
Diabetes  597 (10.1) 417 (69.8) <.001 75 (12.6) .62 0.94 .72–1.20
Immunosuppression  166 (2.8)  85 (51.2) .5 18 (10.8) .36 0.79 .47–1.27
Number of risk groups (comorbidities) 
 1 (reference) 3693 (62.5) 1440 (39.0) <.001  490 (13.3) .71 NA NA
 2 1042 (17.6)  632 (60.7) 141 (13.5 1.02 .83–1.25
 3  705 (11.9)  461 (65.4)  95 (13.5) 1.02 .80–1.28
 4  333 (5.6)  241 (72.4)  39 (11.7) 0.87 .60–1.21
 5  112 (1.2)  81 (72.3)  11 (9.8) 0.71 .36–1.28
 6  25 (0.4)  19 (76.0)  5 (20.0) 1.63 .54–4.06
Influenza vaccine in previous season
 Yes 3352 (56.7) 2417 (72.1) <.001 392 (11.7) <.001 0.74 .64–.86
 No (reference) 2558 (43.3)  457 (17.9) 389 (15.2) NA NA
Swab samples taken in general practices or hospitals
 General practice (reference) 873 (14.8) 359 (41.1) <.001 146 (16.7) .0005 NA NA
 Hospital 5010 (84.8) 2494 (49.8)  628 (12.5) 0.71 .59–.87
 Unknown  27 (0.5)  21 (77.8)  7 (25.9) 1.74 .67–4.02
All P values were estimated using the χ2 test.
Abbreviation: NA, not applicable.
aAdjusted for gender, age, and socioeconomic deprivation.
bAge group available for 5909 swabs.
cDeprivation score only available for 5785 swabs.
dMost socioeconomically deprived.
eUrban/rural score only available for 5824 swabs.
fRemote rural areas.
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low VE estimate of 29.3% (95% CI, 1.0 to 49.4) was detected 
for influenza A(H3), but no heterogeneity was found (Figure 
4). A  higher pooled VE of 48.4% (95% CI, 19.4 to 66.9) was 
found against influenza A(H1N1) compared with influenza 
A(H3). Low-to-moderate heterogeneity was observed across 
seasons (Figure 5). The highest pooled VE of 60.8% (95% CI, 
31.6 to 77.5) was detected for influenza B. Higher heterogeneity 
was also observed for influenza B compared with other strains 
Table 3. Vaccine Effectiveness for Laboratory-Confirmed Influenza Type and Subtype by Season, Scotland, 2010–2016
Dominant Circulating 
Strain(s) for Each 
Influenza Season
Influenza Type  
and Subtype
Influenza-Positive  
(Cases) Influenza-Negative (Controls)
Total  
Positive 
(%)
Unadjusted Vaccine 
Effectivenessa 
(95% CI)
Adjusted Vaccine 
Effectivenessb 
(95% CI)
Vaccinated/ 
Total (n)
Vaccinated 
(%)
Vaccinated/ 
Total (n)
Vaccinated 
(%)
Season: 2010–2011 
A/California/07/2009 
(H1N1)pdm2009 
B/Brisbane/60/2008
Influenza A and B 29/123 23.6 176/364 48.4 25.3 70.1 
(49.5 to 82.3)
76.1 
(55.6 to 87.1)
A(H3) 0/0 0.0 205/487 42.1 0.0 0.0 
(−Inf to 100)
0.0 
(−Inf to 100)
A(H1N1) 17/79 21.5 188/408 46.1 16.2 68.8 
(37.9 to 84.3)
70.7 
(32.5 to 87.3)
Influenza B 5/26 19.2 200/461 43.4 5.3 78.0 
(37.3 to 92.3)
83.2 
(44.3 to 94.9)
Season: 2011–2012 
A/Victoria/208/2009 
(H3N2)
Influenza A and B 14/28 50.0 241/546 44.1 4.9 34.4 
(−44.3 to 70.1)
45.1 
(−35.1 to 77.7)
A(H3) 6/11 54.6 249/563 44.2 1.9 20.1 
(−173.0 to 76.6)
3.7 
(−240.5 to 75.0)
A(H1N1) 0/0 0.0 255/574 44.4 0.0 0.0 
(−Inf to 100)
0.0 
(−Inf to 100)
Influenza B 2/5 40.0 253/569 44.5 0.9 57.1 
(−186.7 to 93.6)
71.8 
(−358.1 to 98.3)
Season: 2012–2013 
A/Victoria/208/2009 
(H3N2) 
A/St 
Petersburg/27/2011 
(H1N1) 
B/Brisbane/60/2008 
B/Brisbane/3/2007 
B/Massachusetts/ 
02/2012
Influenza A and B 50/143 35.0 323/691 46.7 17.2 48.2 
(22.2 to 65.5)
45.2 
(13.8 to 65.1)
A(H3) 17/45 37.8 356/789 45.1 5.4 27.9 
(−36.3 to 61.9)
38.0 
(−25.7 to 69.4)
A(H1N1) 3/17 17.7 370/817 45.3 2.0 79.8 
(28.3 to 94.3)
77.5 
(9.8 to 94.4)
Influenza B 18/53 34.0 355/781 45.5 6.4 40.0 
(−9.8 to 67.3)
11.7 
(−70.7 to 54.3)
Season: 2013–2014 
A/California/07/2009 
(H1N1)pdm09
Influenza A and B 26/54 48.2 457/878 52.1 5.8 37.7 
(−10.7 to 64.9)
52.3 
(6.5 to 75.6)
A(H3) 2/6 33.3 481/926 51.9 0.6 65.9 
(−105.0 to 94.3)
−3.9 
(−1304.5 to 92.3)
A(H1N1) 18/34 52.9 465/898 51.8 3.7 21.4 
(−59.2 to 61.2)
32.0 
(−52.2 to 69.6)
Influenza B 2/5 40.0 481/927 51.9 0.5 45.2 
(−259.1 to 91.7)
100 
(0 to 100)
Season: 2014–2015 
A/Texas/50/2012 
(H3N2) 
B/Yamagata/16/88
Influenza A and B 122/232 52.6 605/1181 51.2 16.4 36.3 
(13.3 to 53.2)
48.6 
(27.8 to 63.4)
A(H3) 79/140 56.4 648/1273 50.9 9.9 21.1 
(−16.0 to 46.4)
26.4 
(−12.0 to 51.6)
A(H1N1) 5/6 83.3 722/1407 51.3 0.4 −290.9 
(−3301.3 to 55.1)
−157.0 
(−2565.5 to 75.2)
Influenza B 20/49 40.8 707/1364 51.8 3.5 62.0 
(30.3 to 79.3)
77.0 
(53.9 to 88.5)
Season: 2015–2016 
A/California/07/2009 
(H1N1)pdm09 
B/Brisbane/60/2008
Influenza A and B 85/201 42.3 746/1469 50.8 12.0 54.8 
(37.8 to 67.1)
57.8 
(40.1 to 70.3)
A(H3) 2/6 33.3 829/1664 49.8 0.4 39.0 
(−294.0 to 90.5)
78.1 
(−102.6 to 97.6)
A(H1N1) 51/104 49.0 780/1566 49.8 6.2 32.8 
(−2.0 to 55.7)
36.7 
(−.6 to 60.2)
Influenza B 26/67 38.8 805/1603 50.2 4.0 60.9 
(33.9 to 76.8)
54.7 
(19.5 to 74.5)
There are cases with unknown influenza A subtype, which explains why the total influenza A(H3) and A(H1N1) samples do not add up exactly to the total influenza A samples.
Abbreviation: CI, confidence interval; Inf, Infinite. 
aAdjusted for time (ie, days) only.
bAdjusted for time (ie, days), age, number of risk groups, and swab location (ie, general practice or hospital).
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but it was nonsignificant. An unadjusted OR was used for the 
2013/2014 season due to zero adjusted OR. This happened due 
to low circulating levels of influenza B strains resulting in small 
to zero OR, which would have prohibited the provision of any 
meaningful OR in the meta-analysis and a subsequent VE esti-
mation (Figure 6).
Vaccine Effectiveness by Age Group
This analysis showed that in those aged ≥55 years the VE was 
low against influenza A subtypes, except those aged 65–74 years 
for A(H1N1), while high VEs for influenza B were found. VE 
was high in children (aged <18  years), with a VE of 90.5% 
against A(H1N1) (Table 4).
DISCUSSION
During 6 influenza seasons, influenza vaccination effective-
ness was greater than 50% for laboratory-confirmed influenza 
in people with asthma. Better protection was observed during 
seasons with good antigenic match and against the A(H1N1) 
and B strains. Moderate VE was found against influenza 
A(H1N1) (47%) and influenza B (62%), and VE was low for in-
fluenza A(H3N2) (34%). In younger adults (aged 18–54 years), 
the seasonal influenza vaccine provided protection against in-
fluenza A(H1N1), influenza A(H3) subtypes, and influenza B.
The highest VE was observed in 2010/2011, which was char-
acterized by high influenza activity predominated by the influ-
enza A(H1N1) and B strains in the United Kingdom [22, 23]. 
While low VE was detected in 2011/2012, this is likely due to 
low and late activity of the predominant A(H3) strain and an 
antigenic vaccine mismatch [24]. Intraseasonal VE waning 
and low VE against A(H3N2) was observed in the United 
Kingdom and the United States [8, 25, 26]. This lower VE has 
been attributed to antigenic drift [26]. In the 2012/2013 season, 
good protection was found only against the A(H1N1) strain; 
this was consistent with the findings from another UK study 
[27]. Antigenic drift for influenza B and VE decline for influ-
enza A(H3N2), particularly in the second trimester following 
Figure 3. Vaccine effectiveness against laboratory-confirmed overall influenza (influenza A and B) by season. *Season with poorly matched vaccine. ^Season with high 
influenza attack rate. Abbreviations: CI, confidence interval; VE, vaccine effectiveness.
Figure 4. Vaccine effectiveness against laboratory-confirmed influenza A(H3) subtype by season. *Season with poorly matched vaccine. ^ Season with high influenza attack 
rate. Abbreviations: CI, confidence interval; VE, vaccine effectiveness.
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vaccination, was noted during this season [27, 28]. A US study 
that included 1259 people with asthma reported a moderate VE 
of 46% in 2012/2013 [8, 29].
We found overall protection against influenza in 2013/2014 
when the influenza activity was low and prolonged, influenza 
A(H1N1) dominated, and the vaccine was well matched [30]. 
In 2014/2015, there was vaccine strain mismatch for H3N2, and 
we observed a positive VE for influenza B that was similar to 
findings in a UK-wide study [31]. In the 2015/2016 season, our 
finding of an overall positive VE is consistent with the VE of 
55% found in a UK study [32]. The influenza A(H1N1) strain 
predominated, and the vaccine was well matched for this sub-
type [33]. We also observed a high VE against influenza B de-
spite lineage mismatch with the vaccine, which was also found 
in another study [32].
The overall VE of 46% in children in this study was similar 
to a recent TND study in Canada where the VE was 43% in 
children [11]. However, in our study, protection was found only 
against the B strain, while previous studies have also shown 
protection against A(H1N1) [34, 35]. Lower strain-specific pro-
tection was observed in older adults (aged ≥55 years), and no 
protection was found against influenza A strains. Nevertheless, 
the VE decrease in those aged ≥55 years may only be indicative 
of immunosenescence, and additional studies that are better 
powered to investigate this phenomenon are needed. There 
is evidence that the VE in those aged >75 years may be lower 
than in those aged 65–74 years [36]. The mechanism for this is 
uncertain but may be explained by reduced immune respon-
siveness to historically used influenza antigens in the most eld-
erly individuals [36]. Such evidence has led to the development 
and introduction of either adjuvanted influenza vaccines or 
high-dose influenza vaccines in this age group. In addition, the 
effects of other factors, such as the presence of other underlying 
conditions in older persons, could explain the decrease in VE 
estimates in this age group.
The strengths of this study include the influenza diagnosis 
based on a test with high predictive value and reduction of any 
recall or misclassification bias due to documentation of vacci-
nation and medical condition status in high-quality electronic 
medical records [37]. Additionally, the TND study minimized 
the effects of selection bias due to differential healthcare-seeking 
behavior between cases and controls by assessing only the 
Figure 6. Vaccine effectiveness against laboratory-confirmed influenza B subtype by season. *Season with poorly matched vaccine. ^Season with high influenza attack 
rate. Abbreviations: CI, confidence interval; VE, vaccine effectiveness.
Figure 5. Vaccine effectiveness against laboratory-confirmed influenza A(H1N1) subtype by season. *Season with poorly matched vaccine. ^Season with high influenza 
attack rate. Abbreviations: CI, confidence interval; VE, vaccine effectiveness.
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prevention of the vaccine against medically attended influenza. 
The inclusion of 6 seasons increased the power of the study, 
allowing the provision of VE estimates for different seasons, 
strains, and patient characteristics. Thus, this study’s findings 
can be generalized to the wider asthma population in Scotland.
Several limitations also need to be considered in this study. 
The VE in this study assessed only the prevention of influenza. 
However, vaccinated individuals may have also benefited by 
having less severe influenza illness and a subsequent lower risk 
of a severe asthma attack. Thus, vaccine protection provided 
Table 4. Vaccine Effectiveness for Laboratory-Confirmed Influenza by Various Age Groups, Scotland, 2010–2016
Age, y 
Influenza Type  
and Subtype
Influenza-Positive  
(Cases)
Influenza-Negative  
 (Controls)
Total  
Positive (%)
Unadjusted Vaccine 
Effectivenessa 
(95% CI)
Adjusted Vaccine 
Effectivenessb 
 (95% CI) 
Vaccinated/ 
Total (n)
Vaccinated 
(%)
Vaccinated/ 
Total (n)
Vaccinated 
(%)
All ages Influenza A and B 326/781 41.7 2548/5129 49.7 13.2 48.6 
(39.2 to 56.6)
55.0 
(45.8 to 62.7)
A(H3) 106/208 51.0 2768/5701 48.5 3.5 26.0 
(−.8 to 45.6)
33.8 
(6.7 to 53.1)
A(H1N1) 94/240 39.2 2780/5670 49.0 4.1 43.2 
(23.6 to 57.8)
46.6 
(25.4 to 61.8)
Influenza B 73/205 35.6 2801/5705 49.1 3.5 59.0 
(44.2 to 70.0)
61.5 
(45.7 to 72.7)
≤17 Influenza A and B 31/101 30.7 368/974 37.8 9.4 52.9 
(23.4 to 71.0)
46.0 
(11.2 to 67.2)
A(H3) 8/26 30.8 391/1049 37.3 2.4 55.7 
(−11.0 to 82.3)
51.1 
(−25.4 to 80.9)
A(H1N1) 4/15 26.7 395/1060 37.3 1.4 64.9 
(−66.8 to 92.6)
90.5 
(−45.3 to 99.4)
Influenza B 12/45 26.7 387/1030 37.6 4.2 69.6 
(26.1 to 87.5)
56.3 
(3.8 to 80.2)
18–54 Influenza A and B 94/376 25.0 733/2093 35.0 15.2 54.0 
(39.2 to 65.2)
57.0 
(42.3 to 68.0)
A(H3) 22/84 26.2 805/2385 33.8 3.4 58.4 
(28.4 to 75.8)
53.3 
(17.9 to 73.5)
A(H1N1) 33/143 23.1 794/2326 34.1 5.8 45.7 
(14.4 to 65.5)
53.0 
(23.8 to 71.1)
Influenza B 22/89 24.7 805/2380 33.8 3.6 49.9 
(15.9 to 70.1)
54.5 
(21.1 to 73.7)
55–64 Influenza A and B 51/104 49.0 384/667 57.6 13.5 51.1 
(22.0 to 69.4)
57.6 
(29.6 to 74.5)
A(H3) 18/29 62.1 417/742 56.2 3.8 2.6 
(−145.9 to 61.4)
2.1 
(−178.5 to 65.6)
A(H1N1) 17/33 51.5 418/738 56.6 4.3 38.0 
(−36.3 to 71.8)
38.7 
(−43.4 to 73.8)
Influenza B 7/24 29.2 428/747 57.3 3.1 78.7 
(45.0 to 91.8)
88.2 
(61.2 to 96.4)
65–74 Influenza A and B 61/91 67.0 488/656 74.4 12.2 54.8 
(22.5 to 73.6)
56.8 
(24.0 to 74.9)
A(H3) 18/24 75.0 531/723 73.4 3.2 −13.4 
(−249.3 to 63.2)
1.0 
(−196.9 to 67.0)
A(H1N1) 22/30 73.3 527/717 73.5 4.0 57.5 
(−37.4 to 86.9)
60.5 
(−37.9 to 88.7)
Influenza B 12/20 60.0 537/727 73.9 2.7 65.3 
(9.0 to 86.8)
65.8 
(5.2 to 87.6)
≥75 Influenza A and B 89/109 81.7 575/739 77.8 12.9 48.9 
(4.8 to 72.5)
51.9 
(9.2 to 74.5)
A(H3) 40/45 88.9 624/803 77.7 5.3 −13.5 
(−232.9 to 61.3)
−15.4 
(−278.2 to 64.8)
A(H1N1) 18/19 94.7 646/829 77.9 2.2 −542.3 
(−6752.7 to 39.8)
−501.0 
(−5639.5 to 37.1)
Influenza B 20/27 74.1 644/821 78.4 3.2 67.6 
(15.1 to 87.6)
70.4 
(19.8 to 89.1)
Abbreviation: CI, confidence interval.
aAdjusted for time within a season (ie, days).
bAdjusted for time (ie, days), age, number of risk groups, and swab location (ie, general practitioner or hospital).
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by a decrease in influenza severity cannot be quantified in 
this study [14, 16, 38]. Although the electronic health records 
from general practices include vaccinations that take place in 
nongeneral practice settings, there may be some misclassifica-
tion of vaccination status. Results from the post hoc analyses 
need careful interpretation since they were not prespecified in 
this study’s protocol. Unmeasured confounders could still have 
influenced the VE estimates. Future research should assess the 
confounding effect on VE from TND studies. TND studies offer 
an elegant way to deal with selection bias related to healthcare-
seeking behavior between cases and control. However, bias may 
occur due to differences in healthcare-seeking behavior be-
tween vaccinated and unvaccinated patients, and swab testing 
may also differ between vaccinated and nonvaccinated patients, 
particularly in nonsentinel settings [39].
In this study, we showed that vaccination can prevent in-
fluenza in individuals with asthma who present with ILI in 
Scottish primary and secondary care settings. While substan-
tial variation in VE was observed among circulating strains and 
age groups, protection was still observed in most subgroups. 
There was significant pooled VE when the A(H1N1) strain 
dominated, which could be explained by the absence of vac-
cine mismatch over the 3 seasons [23, 30, 33]. The lower pooled 
VE when the A(H3) strain dominated could be due to vaccine 
mismatch in most seasons and the intraseasonal VE waning 
[27, 30]. Generally, the protection against A(H3N2) is usually 
lower compared with A(H1N1) and B, which is around 60% 
or even higher [40]. Thus, evidence from this study reinforces 
the recommendation for annual seasonal vaccination in asthma 
patients. Although there are current developments toward uni-
versal vaccines with better potency, durability, and wide pro-
tection, these vaccines may not be available for another decade 
[41]. Thus, monitoring of the effectiveness of current vaccines 
should be continued. Further adequately powered studies will 
be needed to monitor the effectiveness of these vaccines in pop-
ulation groups that are at risk of severe influenza and complica-
tions such as asthma.
The findings of this study can guide research and policy 
makers for the provision of a more targeted and effective vac-
cination program, improving the current protection of the 
asthma population. Specifically, policy makers and clinicians 
should consider adjuvant vaccine or high-dose influenza vac-
cine in people with asthma aged ≥55 years [9]. Healthcare pro-
viders and people with asthma will also have a clearer answer 
regarding the value of influenza vaccination, which is preven-
tion of influenza infection in children and adults with current 
asthma.
In summary, we provide compelling national evidence over 
a number of years that influenza vaccination substantially re-
duces the risk of influenza in people with asthma. There is a 
need for strategies to boost influenza vaccination uptake in 
people with asthma.
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